Cargando…
Six-Month Follow-Up of Immune Responses after a Rapid Mass Vaccination against SARS-CoV-2 with BNT162b2 in the District of Schwaz/Austria
In response to a large outbreak of the SARS-CoV-2 Beta (B.1.351) variant in the district Schwaz, Austria, a rapid mass vaccination campaign with BNT162b2 was carried out in spring 2021, immunizing more than 70% of the adult population within one week. Subsequent analysis revealed that the mass vacci...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414611/ https://www.ncbi.nlm.nih.gov/pubmed/36016265 http://dx.doi.org/10.3390/v14081642 |
_version_ | 1784776030721933312 |
---|---|
author | Bánki, Zoltán Seekircher, Lisa Falkensammer, Barbara Bante, David Schäfer, Helena Harthaller, Teresa Kimpel, Janine Willeit, Peter von Laer, Dorothee Borena, Wegene |
author_facet | Bánki, Zoltán Seekircher, Lisa Falkensammer, Barbara Bante, David Schäfer, Helena Harthaller, Teresa Kimpel, Janine Willeit, Peter von Laer, Dorothee Borena, Wegene |
author_sort | Bánki, Zoltán |
collection | PubMed |
description | In response to a large outbreak of the SARS-CoV-2 Beta (B.1.351) variant in the district Schwaz, Austria, a rapid mass vaccination campaign with BNT162b2 was carried out in spring 2021, immunizing more than 70% of the adult population within one week. Subsequent analysis revealed that the mass vaccination was associated with a significant reduction in new SARS-CoV-2 infections compared to control districts. Here, we aimed to evaluate both SARS-CoV-2-specific T- and B-cell responses at 35 ± 8 and 215 ± 7 days after the second dose in 600 study subjects who participated at both time points. Overall, a robust antibody and T-cell response was measured at day 35, which waned over time. Nevertheless, all persons preserved seropositivity and T cell response could still be detected in about half of the participants at day 215. Further, antibody response correlated negatively with age; however, in persons who experienced SARS-CoV-2 infection prior to study enrolment, the serum levels of both S- and N-specific antibodies surprisingly increased with age. In contrast, there was no correlation of T cell response with age. We could not detect any sex-related difference in the immune responses. SARS-CoV-2 infections prior to study enrolment or incident infections before day 215 resulted in higher antibody levels and T cell responses at day 215 compared to study participants with no history of infection. Collectively, our data support that vaccination with BNT162b2 against COVID-19 provides a durable immune response and emphasize the usefulness of vaccination even after a natural infection. |
format | Online Article Text |
id | pubmed-9414611 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94146112022-08-27 Six-Month Follow-Up of Immune Responses after a Rapid Mass Vaccination against SARS-CoV-2 with BNT162b2 in the District of Schwaz/Austria Bánki, Zoltán Seekircher, Lisa Falkensammer, Barbara Bante, David Schäfer, Helena Harthaller, Teresa Kimpel, Janine Willeit, Peter von Laer, Dorothee Borena, Wegene Viruses Article In response to a large outbreak of the SARS-CoV-2 Beta (B.1.351) variant in the district Schwaz, Austria, a rapid mass vaccination campaign with BNT162b2 was carried out in spring 2021, immunizing more than 70% of the adult population within one week. Subsequent analysis revealed that the mass vaccination was associated with a significant reduction in new SARS-CoV-2 infections compared to control districts. Here, we aimed to evaluate both SARS-CoV-2-specific T- and B-cell responses at 35 ± 8 and 215 ± 7 days after the second dose in 600 study subjects who participated at both time points. Overall, a robust antibody and T-cell response was measured at day 35, which waned over time. Nevertheless, all persons preserved seropositivity and T cell response could still be detected in about half of the participants at day 215. Further, antibody response correlated negatively with age; however, in persons who experienced SARS-CoV-2 infection prior to study enrolment, the serum levels of both S- and N-specific antibodies surprisingly increased with age. In contrast, there was no correlation of T cell response with age. We could not detect any sex-related difference in the immune responses. SARS-CoV-2 infections prior to study enrolment or incident infections before day 215 resulted in higher antibody levels and T cell responses at day 215 compared to study participants with no history of infection. Collectively, our data support that vaccination with BNT162b2 against COVID-19 provides a durable immune response and emphasize the usefulness of vaccination even after a natural infection. MDPI 2022-07-27 /pmc/articles/PMC9414611/ /pubmed/36016265 http://dx.doi.org/10.3390/v14081642 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bánki, Zoltán Seekircher, Lisa Falkensammer, Barbara Bante, David Schäfer, Helena Harthaller, Teresa Kimpel, Janine Willeit, Peter von Laer, Dorothee Borena, Wegene Six-Month Follow-Up of Immune Responses after a Rapid Mass Vaccination against SARS-CoV-2 with BNT162b2 in the District of Schwaz/Austria |
title | Six-Month Follow-Up of Immune Responses after a Rapid Mass Vaccination against SARS-CoV-2 with BNT162b2 in the District of Schwaz/Austria |
title_full | Six-Month Follow-Up of Immune Responses after a Rapid Mass Vaccination against SARS-CoV-2 with BNT162b2 in the District of Schwaz/Austria |
title_fullStr | Six-Month Follow-Up of Immune Responses after a Rapid Mass Vaccination against SARS-CoV-2 with BNT162b2 in the District of Schwaz/Austria |
title_full_unstemmed | Six-Month Follow-Up of Immune Responses after a Rapid Mass Vaccination against SARS-CoV-2 with BNT162b2 in the District of Schwaz/Austria |
title_short | Six-Month Follow-Up of Immune Responses after a Rapid Mass Vaccination against SARS-CoV-2 with BNT162b2 in the District of Schwaz/Austria |
title_sort | six-month follow-up of immune responses after a rapid mass vaccination against sars-cov-2 with bnt162b2 in the district of schwaz/austria |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414611/ https://www.ncbi.nlm.nih.gov/pubmed/36016265 http://dx.doi.org/10.3390/v14081642 |
work_keys_str_mv | AT bankizoltan sixmonthfollowupofimmuneresponsesafterarapidmassvaccinationagainstsarscov2withbnt162b2inthedistrictofschwazaustria AT seekircherlisa sixmonthfollowupofimmuneresponsesafterarapidmassvaccinationagainstsarscov2withbnt162b2inthedistrictofschwazaustria AT falkensammerbarbara sixmonthfollowupofimmuneresponsesafterarapidmassvaccinationagainstsarscov2withbnt162b2inthedistrictofschwazaustria AT bantedavid sixmonthfollowupofimmuneresponsesafterarapidmassvaccinationagainstsarscov2withbnt162b2inthedistrictofschwazaustria AT schaferhelena sixmonthfollowupofimmuneresponsesafterarapidmassvaccinationagainstsarscov2withbnt162b2inthedistrictofschwazaustria AT harthallerteresa sixmonthfollowupofimmuneresponsesafterarapidmassvaccinationagainstsarscov2withbnt162b2inthedistrictofschwazaustria AT kimpeljanine sixmonthfollowupofimmuneresponsesafterarapidmassvaccinationagainstsarscov2withbnt162b2inthedistrictofschwazaustria AT willeitpeter sixmonthfollowupofimmuneresponsesafterarapidmassvaccinationagainstsarscov2withbnt162b2inthedistrictofschwazaustria AT vonlaerdorothee sixmonthfollowupofimmuneresponsesafterarapidmassvaccinationagainstsarscov2withbnt162b2inthedistrictofschwazaustria AT borenawegene sixmonthfollowupofimmuneresponsesafterarapidmassvaccinationagainstsarscov2withbnt162b2inthedistrictofschwazaustria |